Open, Randomized, Phase II, Clinical Trial to Compare the Immunogenicity and Safety of a Booster Dose of GSK Biologicals' DTaP-IPV Vaccine (Infanrix®-IPV) Co-administered With a Booster Dose of Merck and Company's M-M-R®II, to That of Separate Injections of GSK Biologicals' DTaP Vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II Administered as Booster Doses to Healthy Children 4 to 6 Years of Age.
Latest Information Update: 05 Sep 2023
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Measles mumps and rubella virus vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2011 New trial record